SER-252 Advances as the Bullish Case Moves From Platform Promise to Clinical Execution
For a small biotechnology company, progress is best measured in patients dosed, safety reviews completed and the quality of the next clinical question. By those measures, Serina Therapeutics (NYSE American:…